menu
    • menu

    Company profile for Immuron

    NEW Drugs in Dev: 6
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steato...
    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmuronAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131
    Telephone
    Telephone
    +613 8892 4802
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immuron.com.au/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immuronltd/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ImmuronLtd?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuron CEO Steven Lydeamore to Present at Coffee Microcaps
    Immuron CEO Steven Lydeamore to Present at Coffee Microcaps

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249948/37134/en/Immuron-CEO-Steven-Lydeamore-presentation-at-Coffee-Microcaps-Conference.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Immuron Reports HY26 Results And Strategic Reset
    Immuron Reports HY26 Results And Strategic Reset

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244392/37134/en/Immuron-Reports-HY26-Results-and-Strategic-Reset.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Immuron Reports Continued Sales Growth
    Immuron Reports Continued Sales Growth

    19 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/19/3220851/37134/en/Immuron-Reports-Continued-Sales-Growth.html

    GLOBENEWSWIRE
    19 Jan 2026
    Share Share
    Immuron Secures Dod Award & Updates Clinical Trial
    Immuron Secures Dod Award & Updates Clinical Trial

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198692/37134/en/Immuron-New-U-S-Department-of-Defense-Award-Clinical-Trial-Update.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Immuron IMM-529 IND Approved By FDA
    Immuron IMM-529 IND Approved By FDA

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181195/37134/en/Immuron-IMM-529-IND-approved-by-FDA.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Immuron Announces Clinical Trial Update
    Immuron Announces Clinical Trial Update

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178196/37134/en/Immuron-Announces-Clinical-Trial-Update.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search